Da Zhang

Dr. Da Zhang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Frontiers in Artificial Intelligence
Verified
Journal Article
Open access
PDF file
YTYukun Tao
Yukun Tao
JHJinzheng Hou
Jinzheng Hou
GZGuangxin Zhou
Guangxin Zhou
DZDa Zhang
Da Zhang
Background and aims: Artificial intelligence (AI)-driven medical assistive technology has been widely used in the diagnosis, treatment and prognosis of diabetes complications. Here we conduct a bibliometric analysis of scientific articles in the field of AI in diabetes complications to explore current research trends and cutting-edge hotspots.Methodology: On April 20, 2024, we collected and screened relevant articles published from 1988 to 2024 from PubMed. Based on bibliometric tools such as CiteSpace, Vosviewer and bibliometix, we construct knowledge maps to visualize literature information, including annual scientific production, authors, countries, institutions, journals, keywords and research hotspots.Results: A total of 935 articles meeting the criteria were collected and analyzed. The number of annual publications showed an upward trend. Raman, Rajiv published the most articles, and Webster, Dale R had the highest collaboration frequency. The United States, China, and India were the most productive countries. Scientific Reports was the journal with the most publications. The three most frequent diabetes complications were diabetic retinopathy, diabetic nephropathy, and diabetic foot. Machine learning, diabetic retinopathy, screening, deep learning, and diabetic foot are still being researched in 2024.Conclusion: Global AI research on diabetes complications is expected to increase further. The investigation of AI in diabetic retinopathy and diabetic foot will be the focus of research in the future.

4 January 2024 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
YYYuanyuan Yu
Yuanyuan Yu
GZGuangxin Zhou
Guangxin Zhou
JDJunjie Du
Junjie Du
HZHuijuan Zhu
Huijuan Zhu
HGHaojun Guan
Haojun Guan
DZDa Zhang
Da Zhang
With the widespread vaccination of COVID-19 vaccine, a few cases have been reported that COVID-19 vaccine may cause endocrine disorders. A 59-y-old man presented with a loss of appetite after the first COVID-19 vaccination, which resolved spontaneously after 3 d. After the second COVID-19 vaccination, the symptoms including the loss of appetite, nausea, and vomiting reappeared and worsened along with loss of vision. He was found to have severe hyponatremia, and further investigations revealed secondary adrenal insufficiency, secondary hypothyroidism and Rathke's cleft cyst. The patient responded well to glucocorticoid and levothyroxine supplementation, and at 1-y follow-up the patient developed hypogonadism. We hypothesize that hypophysitis is probably induced by COVID-19 vaccine and report the rare but serious adverse reactions for early recognition and intervention.

28 February 2022 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
DZDa Zhang
Da Zhang
LLLin Lu
Lin Lu
HZHuijuan Zhu
Huijuan Zhu
YXYu Xiao
Yu Xiao
XHXianlin Han
Xianlin Han
ZLZhao-Lin Lu
Zhao-Lin Lu
Objectives. To analyze and summarize the effect of SSA treatment on EAS due to p-NETs (EAS-p-NETs). Methods. Thirteen patients with EAS-p-NETs treated with SSAs at our center or described in the literature were included in this study. Clinical characteristics, laboratory data, imaging studies, histopathologic results, the effect of SSA treatment, and the prognosis of these EAS-p-NET patients were evaluated. Results. Four males and 9 females with an average age of 42.9 years were included in the study. The mean duration of follow-up was 38.8±28.2 months. As one of the combined treatment measures, SSAs controlled the levels of ACTH and cortisol in 9 of the 13 patients (69.2). Partial response was observed in 3 patients (23.1), stable disease in 2 patients (15.4), and progressive disease in 6 patients (46.2). The median time to tumor progression was 24 months, and the median overall survival was 61 months. The side effects of SSA treatment included temporary mild abdominal pain, diarrhea, gallstones, and cholecystitis. Conclusions. As a supplemental therapy, SSA treatment led to clinical and biochemical improvement with a good safety profile in patients exhibiting EAS-p-NET with metastasis. However, tumor progression was inhibited by SSA treatment in only a few patients. Combined with other treatments, SSAs may improve the prognosis of patients with EAS-p-NETs.

26 January 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
GZGuang-Xin Zhou
Guang-Xin Zhou
LXLi Xiao
Li Xiao
YBYong-Min Bi
Yong-Min Bi
FYFen Yang
Fen Yang
CYCai-Zhe Yang
Cai-Zhe Yang
DZDa Zhang
Da Zhang
We present the case of a 54-year-old woman with reasonable blood sugar control who presented with a diabetic foot combined with severe peripheral neuropathy and vascular disease. Lower limb muscle weakness, muscle atrophy, skin pigmentation, and emaciation were also observed. Although her muscle strength improved after glucocorticoid treatment, it remained challenging to account for the other symptoms in this particular patient with chronic inflammatory demyelinating polyneuropathy. Plump liver and spleen, hidden bone lesions combined with seemingly unexplained cerebral infarction, and serous effusion led us to suspect polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. The abnormal proliferation of monoclonal plasma cells and a significant increase in vascular endothelial growth factor (VEGF) levels confirmed the diagnosis of POEMS syndrome. After 1 month of treatment with lenalidomide and dexamethasone, the diabetic foot ulcers healed, and the symptoms of myasthenia and fatigue improved. Diabetic feet may represent only the tip of the iceberg of an underlying POEMS syndrome. Our report aimed to increase awareness of this rare yet significant situation, advocating for the prompt identification and treatment of POEMS syndrome.

10 June 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WZWenjing Zhang
Wenjing Zhang
LXLi Xiao
Li Xiao
GZGuangxin Zhou
Guangxin Zhou
HZHuijuan Zhu
Huijuan Zhu
YBYongmin Bi
Yongmin Bi
DZDa Zhang
Da Zhang
With advancements in medical oncology, immune checkpoint inhibitors (ICIs) have become the first-line treatment for many malignancies. ICIs play a significant role in improving cancer prognosis, but a series of immune-related adverse events (irAEs), including immune-related endocrine events (irEEs), caused by ICIs have also aroused concerns. Rapid clinical identification of irAEs caused by ICIs is particularly important. We describe a case of secondary adrenocortical insufficiency (AI) after PD-1 treatment in a postoperative patient with endometrial cancer. A 73-year-old female patient developed anorexia, nausea, vomiting, malaise, electrolyte disturbances, ineffective symptomatic treatment, and decreased serum adrenocorticotropin and cortisol levels six months after retifanlimab treatment. The vomiting resolved, and the electrolyte levels were corrected after 3 days of treatment with glucocorticoids (hydrocortisone, intravenous, 200 mg/day). When patients present with gastrointestinal symptoms, such as poor appetite and nausea, not only symptomatic treatment but also a search for the etiology behind the symptoms is needed, especially in immunotherapy patients who should undergo a thorough evaluation of the endocrine system and be alert for adrenocortical insufficiency.

2 August 2022 in Medical Teacher
Verified
Journal Article
Open access
DZDa Zhang
Da Zhang
LXLi Xiao
Li Xiao
JDJingqi Duan
Jingqi Duan
XCXinxin Chang
Xinxin Chang
KWKieran Walsh
Kieran Walsh
YCyanjie Cao
yanjie Cao
Understanding self-directed learning (SDL) when using point of care information systems (POCIS) can inform educational providers of the usefulness of the system for continuing medical education (CM...